Literature DB >> 19324009

Immunological study of HA1 domain of hemagglutinin of influenza H5N1 virus.

Fang-Feng Chiu1, Nandini Venkatesan, Chia-Rong Wu, Ai-Hsiang Chou, Hsin-Wei Chen, Shu-Pei Lian, Shih-Jen Liu, Chin-Cheng Huang, Wei-Cheng Lian, Pele Chong, Chih-Hsiang Leng.   

Abstract

The neutralization titer of a hemagglutinin (HA)-specific neutralizing antibody against new isolates reflect both the antigenic drift and the conformation status of HA protein in these new influenza viruses. Since most antigenic sites are in the HA1 domain of HA, using HA1 domain of influenza virus as antigen is of great importance in vaccine development. In this study, we investigate different purification processes for optimizing the immunological properties of an Escherichia coli-expressed HA1 domain (rH5HA1) of influenza H5N1 virus. rH5HA1 was expressed as inclusion bodies and extracted with 6M guanidine hydrochloride (GnHCl)/PBS buffer. The best condition for generating HA1-specific neutralization determinants is on-column oxidative refolding procedures with GSH/GSSG and l-arginine buffer. Others refolding procedures such as using high-pH buffer and/or different detergent solubilizations were found to be ineffective producing neutralization epitope recognized by a HA1-specific neutralizing monoclonal antibody that was raised against H5N1 virus.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19324009     DOI: 10.1016/j.bbrc.2009.03.106

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  22 in total

1.  Vaccination with Killed but Metabolically Active E. coli Over-expressing Hemagglutinin Elicits Neutralizing Antibodies to H1N1 Swine Origin Influenza A Virus.

Authors:  Pei-Feng Liu; Yanhan Wang; Yu-Tsueng Liu; Chun-Ming Huang
Journal:  J Nat Sci       Date:  2017-02

2.  Purification and immunogenicity of hemagglutinin from highly pathogenic avian influenza virus H5N1 expressed in Nicotiana benthamiana.

Authors:  Teen-Lee Pua; Xiao Ying Chan; Hwei-San Loh; Abdul Rahman Omar; Vidadi Yusibov; Konstantin Musiychuk; Alexandra C Hall; Megan V Coffin; Yoko Shoji; Jessica A Chichester; Hong Bi; Stephen J Streatfield
Journal:  Hum Vaccin Immunother       Date:  2016-12-08       Impact factor: 3.452

3.  Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy.

Authors:  Se Mi Kim; Young-Il Kim; Su-Jin Park; Eun-Ha Kim; Hyeok-Il Kwon; Young-Jae Si; In-Won Lee; Min-Suk Song; Young Ki Choi
Journal:  J Virol       Date:  2017-02-28       Impact factor: 5.103

4.  Thermostable tag (TST) protein expression system: engineering thermotolerant recombinant proteins and vaccines.

Authors:  Jeremy M Luke; Aaron E Carnes; Ping Sun; Clague P Hodgson; David S Waugh; James A Williams
Journal:  J Biotechnol       Date:  2010-12-17       Impact factor: 3.307

5.  L-arginine mediated renaturation enhances yield of human, α6 Type IV collagen non-collagenous domain from bacterial inclusion bodies.

Authors:  Venugopal Gunda; Chandra Shekhar Boosani; Raj Kumar Verma; Chittibabu Guda; Yakkanti Akul Sudhakar
Journal:  Protein Pept Lett       Date:  2012-10       Impact factor: 1.890

6.  Specific recognition of influenza A/H1N1/2009 antibodies in human serum: a simple virus-free ELISA method.

Authors:  Mario M Alvarez; Felipe López-Pacheco; José M Aguilar-Yañez; Roberto Portillo-Lara; Gonzalo I Mendoza-Ochoa; Sergio García-Echauri; Pamela Freiden; Stacey Schultz-Cherry; Manuel I Zertuche-Guerra; David Bulnes-Abundis; Johari Salgado-Gallegos; Leticia Elizondo-Montemayor; Martín Hernández-Torre
Journal:  PLoS One       Date:  2010-04-14       Impact factor: 3.240

7.  Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus.

Authors:  Surender Khurana; Swati Verma; Nitin Verma; Corey J Crevar; Donald M Carter; Jody Manischewitz; Lisa R King; Ted M Ross; Hana Golding
Journal:  PLoS One       Date:  2010-07-12       Impact factor: 3.240

8.  An influenza A/H1N1/2009 hemagglutinin vaccine produced in Escherichia coli.

Authors:  José M Aguilar-Yáñez; Roberto Portillo-Lara; Gonzalo I Mendoza-Ochoa; Sergio A García-Echauri; Felipe López-Pacheco; David Bulnes-Abundis; Johari Salgado-Gallegos; Itzel M Lara-Mayorga; Yenny Webb-Vargas; Felipe O León-Angel; Ramón E Rivero-Aranda; Yuriana Oropeza-Almazán; Guillermo M Ruiz-Palacios; Manuel I Zertuche-Guerra; Rebecca M DuBois; Stephen W White; Stacey Schultz-Cherry; Charles J Russell; Mario M Alvarez
Journal:  PLoS One       Date:  2010-07-22       Impact factor: 3.240

9.  H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice.

Authors:  Irina Margine; Rong Hai; Randy A Albrecht; Gerlinde Obermoser; A Carson Harrod; Jacques Banchereau; Karolina Palucka; Adolfo García-Sastre; Peter Palese; John J Treanor; Florian Krammer
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

10.  Influence of copy number on the expression levels of pandemic influenza hemagglutinin recombinant protein in methylotrophic yeast Pichia pastoris.

Authors:  T N Athmaram; Shweta Saraswat; Anil Kumar Singh; M Kameswara Rao; N Gopalan; V V S Suryanarayana; P V L Rao
Journal:  Virus Genes       Date:  2012-09-02       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.